The obesity pandemic poses a unique set of problems for acute pancreatitis -both by increasing acute pancreatitis incidence, and worsening acute pancreatitis severity. This review explores these associations, underlying mechanisms, and potential therapies.
INTRODUCTION
Obesity is a growing pandemic [1] with increasing healthcare costs, and acute pancreatitis is one of the most common gastroenterological causes for hospitalization in the United States affecting 275 000 patients annually [2] . Obesity has likely contributed to increasing the incidence [2, 3] and severity [4] [5] [6] [7] [8] [9] [10] [11] of acute pancreatitis. Here we discuss the underlying mechanisms, and emerging acute pancreatitis management options based on clinically relevant studies.
DISCUSSION
Obesity describes excessive adiposity, and currently afflicts humans in pandemic proportions. Visceral abdominal adiposity has the biggest impact on acute pancreatitis [12,13 && ,14] . Although the definition of obesity varies, on a global scale more than 35% of adults are overweight (BMI > 25 kg/m 2 ) and more than 10% are obese (BMI > 30 kg/m 2 ) [15] . Interestingly, when defined by criteria accepted by national organizations, the proportion with obesity increases. For example, although only about 4% of men in China or Japan, and 34% in the United States have a BMI of more than 30 [15] ; based on waist circumference cutoffs relevant to these countries, more than 35% of adult men in all three countries are obese [16] . Therefore, despite the varying definitions of obesity, the rates of abdominal adiposity are similarly high across the globe. This is important as over the last 3 decades, both the prevalence of obesity [1] and incidence of pancreatitis [3, 17] have increased. Moreover, as we discuss below, obese patients have a higher risk of severe acute pancreatitis (SAP). In the following section, we will separately discuss the pathophysiology of how obesity may increase the incidence, and also worsen the severity of acute pancreatitis.
The several ways by which obesity increases the risk of acute pancreatitis are summarized in Table 1 and are discussed below:
(1) Cholelithiasis: Overweight and obese patients have higher incidence of biliary disease [18 & ,19 & ] and pancreatitis [19 & ]. Biliary disease causes acute pancreatitis by stones, sludge, or microlithiasis in the biliopancreatic passages either causing bile reflux or increasing pancreatic duct pressure [20] . Obesity may impact gallstone formation by multiple mechanisms. A high-fat western diet may predispose to cholesterol-rich crystals or stones in the bile [21] by increasing cholesterol crystal number [22] or growth [23] . This is supported by obese children with biliary pancreatitis having a higher likelihood of stones than sludge [24] . Additional factors may include the decrease in circulating bile acids, and gall bladder stasis from increasing intervals between meals in an attempt to lose weight or prevent obesity [25, 26] . Obesity may also affect diagnosis of gallstones, as one study reports a decreased sensitivity of magnetic resonance cholangiopancreatography in detecting gallstone in obese and overweight patients [27] . (2) ]. The largest series includes 301 patients followed for 6 months, two of whom developed pancreatitis [67] . Pancreatitis may occur from dislodgement or pressure on the pancreas. Interestingly, an emerging therapy for pancreatitis is a rapidly reversible cooling balloon placed in the stomach [68 & ], which cools the pancreas transgastrically and may slow the numerous mechanisms active in pancreatitis simultaneously.
Role of obesity in severity of acute pancreatitis
The severity of acute pancreatitis is typically unrelated to the acute pancreatitis cause [69] [70] [71] [72] . Unlike subcutaneous fat, which rarely impacts the severity of acute pancreatitis [73 && ] obesity associated increase in visceral fat in or around the pancreas can worsen acute pancreatitis outcomes [8, 14, 74, 75] (Fig. 1A,  B) . This can present as hypocalcemia earlier, or as organ failure later in the disease course (Fig. 1C, D) . The resulting damage to visceral fat, described as fat necrosis, is a part of radiographic criteria for pancreatitis severity [76, 77] and the revised Atlanta criteria [78] . Additionally, obesity increases the risk of HTG both preceding and during an attack of pancreatitis [79 & ]. Therefore, obesity can worsen pancreatitis. Patterns of severe pancreatitis noted in obesity:
(1) Local pancreatic necrosis: About 95% of necrotizing pancreatitis involves fat necrosis and pancreatic necrosis [76] [77] [78] 80, 81] , with isolated pancreatic parenchymal necrosis occurring in less than 5% of cases [81] . In obesity, adipocytes within the pancreas (i.e., intrapancreatic fat) increase with BMI [82, 83] and are dispersed fairly uniformly [84] adjacent to the basolateral membranes of the lipase rich exocrine pancreatic acinar cells (Fig. 2) . Although these triglyceride-rich adipocytes are normally not subject to lipolysis because of the apically polarized secretion from acinar cells, this homeostasis is disrupted during acute pancreatitis. The basolateral release of digestive enzymes including lipases into adipocytes damages them [85, 86] and hydrolyzes their triglyceride which forms more than 80% of adipocyte mass [87] [88] [89] . The composition of this triglyceride is predominantly unsaturated in obesity [83,90 && ]. This hydrolysis causes UFAs release from the damaged adipocytes, which in turn causes necrosis of acinar cells by inhibiting mitochondrial complexes I and V [83] . This vicious lipolytic flux causes further acinar damage; perpetuating necrotizing pancreatitis via lipase leak-mediated UFA release. In contrast, adipocyte mass in chronic pancreatitis is unrelated to BMI, and is surrounded by fibrosis, which prevents the lipolytic flux between the two compartments [86] and thereby SAP. (2) Systemic injury including organ failure:
Although about 80% cases of pancreatic necrosis occurs with peripancreatic fat (PPF) necrosis [81, 91] , about 10-15% of cases of moderate-tosevere pancreatitis have PPF necrosis without pancreatic parenchymal necrosis [81, 91] ( Fig. 1b-d) . PPF close to the pancreas, such as perinephric, mesenteric, perisplenic is prone to lipolysis. When extensive, PPF necrosis alone can result in moderate acute pancreatitis to SAP [81, [91] [92] [93] (Fig. 1b-d, Fig. 2 ) and sometimes mortality [94] [95] [96] Mechanisms by which obesity may exacerbate pancreatitis
In obesity, adipose tissue can exceed 30% of body weight [97] with visceral fat comprising more than 3% of body weight [98] . More than 80% of adipocyte mass is triglyceride [87] [88] [89] [103, 104] . Being polar, UFAs are normally bound by calcium, resulting in their saponification and inactivation in fat necrosis. This can result in the hypocalcemia noted during SAP (Fig. 1c) , which is part of Ranson et al.'s [105] , Japanese severity score [106] and the recently validated [107] Glasgow criteria [108] . The remaining unbuffered nonesterified UFAs can increase inflammatory mediators such as tumor necrosis factor (TNF-a), CXC ligand 1 (CXCL1), and CXCL2, and cause necrosis by reducing ATP levels via inhibiting mitochondrial complexes I and V [83] , thus worsening acute pancreatitis. This damage is noted within the pancreas as perifat acinar necrosis [83, 102 && ], forming half of all parenchymal necrosis, and systemically as renal tubular apoptosis associated with renal failure, and dead cells in lung alveoli [83, 90 && ,101,102 && ] similar to acute respiratory distress syndrome [109, 110] (Fig. 2) . Thus uncontrolled UFA release by being proinflammatory and causing cell death seems to be the orchestrator of the cytokine response and release of damage-associated molecular patterns (DAMPs) from dying cells. These are discussed below: (2) [121] [122] [123] . These findings along with the inability of cytokines to induce outcomes relevant to SAP [122] [123] [124] [125] [126] , and the unclear benefit of anti-TNF-a therapies in acute pancreatitis [127] [128] [129] [130] [131] , make cytokines unfavorable therapeutic targets in obesityassociated SAP. (3) DAMPs: DAMPs are released when there is cell injury such as in necrosis. DAMPs include highmobility group box 1 (HMGB1), the soluble receptor for advanced glycation end products, nuclear components (e.g., DNA, nucleosomes, histones), belonging to the S100 protein family, ATP, and extracellular matrix components such as hyaluronan fragments. Hoque et al. [132] first showed the requirement of the DAMP receptors TLR9 (agonist; nucleic acids) and P2X7 (agonist; ATP) in caerulein pancreatitis. Intracellular HMGB1 was later shown to be protective in L-arginine and caerulein pancreatitis [133] . Although serum HMGB1 [134] , soluble receptor for advanced glycation end products [135] , histone [136 & ], and nucleosome [137 & ] levels correlate with human acute pancreatitis severity; it remains unclear whether DAMPs are markers or mediators of SAP outcomes and conclusive studies on them inducing end points that are clinically relevant to SAP need to be done. Potential therapies for obesity related severe acute pancreatitis
(1) Choice of intravenous (IV) fluids: As the initial study by Wu et al. [138] reporting Lactated Ringer's reduces SIRS and C-reactive protein more than saline in acute pancreatitis patients, other studies have shown similar results [139,140 & ]. Potential beneficial mechanisms of Lactated Ringer's include 1) the 3 mEq/l calcium it contains, 2) Lactated Ringer's being buffered whereas saline is not, and 3) the lactate in Lactated Ringer's being a G-protein receptior (GPR81) agonist and thereby reducing inflammasome and nuclear factor kappa B activation [141] . It should be noted that the role of GPR81 has not been studied in obese mice or in the context of organ failure. Additionally, saline has no buffering capacity and is unlikely to influence blood pH. Hypocalcemia is a known complication of SAP [105, 106, 108] (Fig. 1c) . A study comparing extracellular calcium replacement to pH 7.4 buffered lactate showed improved outcomes in the calcium group [142 & ]. Thus Lactated Ringer's benefit is most likely via replacing extracellular calcium which can bind and saponify UFAs. . This includes a reduction in mortality, severe pancreatic necrosis, renal, and respiratory failure. These benefits are also noted in lethal acute pancreatitis induced concurrently with administration of triglycerides containing UFAs found in human pancreatic necrosis [90 && ,101] . However, the only Food and Drug Administrationapproved formulation of the lipase inhibitor, orlistat is oral, which is poorly absorbed (<1%) and is used worldwide as the counter drug for weight loss. For use in SAP, orlistat requires a special parenteral formulation [102 && ], which would be off-label use of the drug. The few case reports of orlistat and pancreatitis [144] [145] [146] over the last decade show a latency period varying from 2 to 10 days and there is no rechallenging data. The evidence against orlistat is thus class III [147] , and is likely coincidental given orlistat's widespread use and the fact that about 20% of acute pancreatitis is idiopathic. These points reinforce the urgent need to develop better agents for use in acute pancreatitis.
CONCLUSION
The growing pandemic of obesity has increased acute pancreatitis's incidence and severity. The increase in incidence is because of increased risk of gallstones, HTG, medications, and weight loss interventions. Obesity worsens acute pancreatitis severity by allowing unregulated lipolysis of visceral fat enriched in unsaturated triglyceride, thus releasing UFAs which inhibit mitochondrial complexes I and V, cause necrosis, and worsen acute pancreatitis. Lactated Ringer's benefit over saline as an IV fluid for managing acute pancreatitis because of the calcium it contains, and whereas definitive measures to prevent and neutralize UFA toxicity are needed, parenteral formulations of orlistat remain a potential option.
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